It is now my pleasure to turn today's program over to Patrick O'Brien, SVP, Investor Relations at Ligand's Pharmaceuticals. Speaking for Ligand today will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.
Bio-Rad Laboratories tops the list Continue reading...
These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q2 2020.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report first quarter 2020 financial results on May 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Q1 2020 Ligand Pharmaceuticals Inc Earnings Call
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Ligand (LGND) reports higher-than-expected first-quarter 2020 earnings and revenues.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations. As previously announced, the purchase price was $15 million in cash, and Icagen is entitled to receive additional cash payments based on certain revenue achievements.
LGND vs. TECH: Which Stock Is the Better Value Option?
Ligand (LGND) delivered earnings and revenue surprises of 45.90% and 27.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
These 3 stocks appear to trade at bargain prices based on 2 key valuation ratios Continue reading...
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provides a general corporate update, as follows:
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that today’s scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured. The webcast will take place as previously scheduled at 2:35 p.m. ET and is available here. Conference one-on-one investor meetings have been moved to telephone calls, and the new slides Ligand will be using during those meetings have been posted to www.ligand.com.
VICTORIA , April 17, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to provide an update on its research activities for the novel coronavirus (SARS-CoV-2) which outlines the Company's workflows for their experimental vaccines and therapeutics for the research community. Hence, IPA anticipates that it can accelerate anti-SARS-CoV-2 human antibody discovery, targeting multiple viral epitopes and mechanisms of viral evasion, by immunizing Ligand's (LGND) OmniRat® animals using the Company's Rapid Prime™ protocol followed by IPA's B cell Select™ and hybridoma generation in parallel with human, naive phage library screening.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors need to pay close attention to Ligand (LGND) stock based on the movements in the options market lately.